ABOUT THIS STUDY
1. Patients diagnosed as advanced renal cell carcinoma (aRCC) after failure of one prior systemic therapy.
2. Patients to whom INLYTA® is first administered or patients who are already on INLYTA® during the study period
3. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
1. Any patient who does not agree that Pfizer and companies working with Pfizer use
2. Patients with hypersensitivity to axitinib or to any other component of INLYTA®
3. Patients under 18
4. Pregnant women
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Nanjing, Jiangsu